Rani Therapeutics Holdings (RANI) Total Liabilities (2020 - 2026)

Rani Therapeutics Holdings has reported Total Liabilities for 7 years, with the latest figure at $12.9 million in Q2 2026.

• On a quarterly basis, Total Liabilities fell 50.64% year-over-year to $12.9 million in Q2 2026; TTM through Jun 2026 was $12.9 million, a 50.64% decrease from a year earlier, with the FY2025 full-year figure at $17.1 million, down 48.38% from the prior year.
• Total Liabilities was $12.9 million for Q2 2026 at Rani Therapeutics Holdings, down from $16.3 million in the prior quarter.
• The five-year high for Total Liabilities was $39.0 million in Q1 2024, with the low at $4.7 million in Q1 2022.
• Average Total Liabilities over 5 years is $26.5 million, with a median of $31.0 million recorded in 2023.
• The largest YoY upside for Total Liabilities was 1188.75% in 2022 against a maximum downside of 96.06% in 2022.
• Over 5 years, Total Liabilities stood at $34.0 million in 2022, then slipped by 4.56% to $32.5 million in 2023, then grew by 2.06% to $33.1 million in 2024, then plunged by 48.38% to $17.1 million in 2025, then decreased by 24.85% to $12.9 million in 2026.
• The last three Total Liabilities figures came in at $12.9 million (Q2 2026), $16.3 million (Q1 2026), and $17.1 million (Q4 2025), per Business Quant data.